Heather J Chalfin1, Seung Bae Lee1, Byong Chang Jeong1, Stephen J Freedland1, Hamid Alai1, Zhaoyong Feng1, Bruce J Trock1, Alan W Partin1, Elizabeth Humphreys1, Patrick C Walsh1, Misop Han2. 1. James Buchanan Brady Urological Institute, Johns Hopkins Medical Institutions, Baltimore, Maryland, Seoul National University Boramae Hospital (SBL), Seoul, South Korea; Sungkyunkwan University Samsung Medical Center (BCJ), Seoul, South Korea; Duke University Medical Center, Durham, North Carolina (SJF). 2. James Buchanan Brady Urological Institute, Johns Hopkins Medical Institutions, Baltimore, Maryland, Seoul National University Boramae Hospital (SBL), Seoul, South Korea; Sungkyunkwan University Samsung Medical Center (BCJ), Seoul, South Korea; Duke University Medical Center, Durham, North Carolina (SJF). Electronic address: mhan1@jhmi.edu.
Abstract
PURPOSE: Obesity is a modifiable risk factor associated with worse outcomes for many cancers, yet implications for prostate cancer are not well understood. Notably the impact of body mass index on long-term survival after treatment is unclear. We performed a retrospective cohort study on a large series of men who underwent radical prostatectomy to assess the impact of obesity on long-term biochemical recurrence-free survival, prostate cancer specific survival and overall survival. MATERIALS AND METHODS: Between 1982 and 2012, 11,152 men underwent radical prostatectomy at a single tertiary referral center. Patients were stratified according to body mass index as normal weight (body mass index less than 25 kg/m(2)), overweight (body mass index 25 to less than 30 kg/m(2)), mild obesity (body mass index 30 to less than 35 kg/m(2)) and moderate/severe obesity (body mass index 35 kg/m(2) or greater), comprising 27.6%, 56.0%, 14.1% and 2.3% of the cohort, respectively. Covariates included age, preoperative prostate specific antigen, surgery year, Gleason score, pathological stage, surgical margin and race. Predictors of biochemical recurrence-free survival, prostate cancer specific survival and overall survival were identified using Cox proportional hazard models. RESULTS: Median followup was 5 years (range 1 to 27). Actuarial 20-year biochemical recurrence-free survival for mild and moderate/severe obesity was 65% and 51%, respectively, compared to 76% for normal weight men (p ≤0.001). In a multivariate model obesity was a significant predictor of biochemical recurrence-free survival (mild HR 1.30, p = 0.002; moderate/severe HR 1.45, p = 0.028) and overall survival (mild HR 1.41, p = 0.003; moderate/severe HR 1.81, p = 0.033). However, only mild obesity was significantly associated with prostate cancer specific survival (HR 1.51, p = 0.040), whereas moderate/severe obesity was not (HR 1.58, p = 0.356). CONCLUSIONS: Obese men have higher rates of biochemical recurrence than normal weight patients during long-term followup. Obesity at the time of surgery independently predicts overall survival and biochemical recurrence-free survival but not prostate cancer specific survival.
PURPOSE:Obesity is a modifiable risk factor associated with worse outcomes for many cancers, yet implications for prostate cancer are not well understood. Notably the impact of body mass index on long-term survival after treatment is unclear. We performed a retrospective cohort study on a large series of men who underwent radical prostatectomy to assess the impact of obesity on long-term biochemical recurrence-free survival, prostate cancer specific survival and overall survival. MATERIALS AND METHODS: Between 1982 and 2012, 11,152 men underwent radical prostatectomy at a single tertiary referral center. Patients were stratified according to body mass index as normal weight (body mass index less than 25 kg/m(2)), overweight (body mass index 25 to less than 30 kg/m(2)), mild obesity (body mass index 30 to less than 35 kg/m(2)) and moderate/severe obesity (body mass index 35 kg/m(2) or greater), comprising 27.6%, 56.0%, 14.1% and 2.3% of the cohort, respectively. Covariates included age, preoperative prostate specific antigen, surgery year, Gleason score, pathological stage, surgical margin and race. Predictors of biochemical recurrence-free survival, prostate cancer specific survival and overall survival were identified using Cox proportional hazard models. RESULTS: Median followup was 5 years (range 1 to 27). Actuarial 20-year biochemical recurrence-free survival for mild and moderate/severe obesity was 65% and 51%, respectively, compared to 76% for normal weight men (p ≤0.001). In a multivariate model obesity was a significant predictor of biochemical recurrence-free survival (mild HR 1.30, p = 0.002; moderate/severe HR 1.45, p = 0.028) and overall survival (mild HR 1.41, p = 0.003; moderate/severe HR 1.81, p = 0.033). However, only mild obesity was significantly associated with prostate cancer specific survival (HR 1.51, p = 0.040), whereas moderate/severe obesity was not (HR 1.58, p = 0.356). CONCLUSIONS: Obese men have higher rates of biochemical recurrence than normal weight patients during long-term followup. Obesity at the time of surgery independently predicts overall survival and biochemical recurrence-free survival but not prostate cancer specific survival.
Authors: Crystal S Denlinger; Jennifer A Ligibel; Madhuri Are; K Scott Baker; Wendy Demark-Wahnefried; Don Dizon; Debra L Friedman; Mindy Goldman; Lee Jones; Allison King; Grace H Ku; Elizabeth Kvale; Terry S Langbaum; Kristin Leonardi-Warren; Mary S McCabe; Michelle Melisko; Jose G Montoya; Kathi Mooney; Mary Ann Morgan; Javid J Moslehi; Tracey O'Connor; Linda Overholser; Electra D Paskett; Jeffrey Peppercorn; Muhammad Raza; M Alma Rodriguez; Karen L Syrjala; Susan G Urba; Mark T Wakabayashi; Phyllis Zee; Nicole R McMillian; Deborah A Freedman-Cass Journal: J Natl Compr Canc Netw Date: 2014-10 Impact factor: 11.908
Authors: Adriana C Vidal; Lauren E Howard; Amanda de Hoedt; Christopher J Kane; Martha K Terris; William J Aronson; Matthew R Cooperberg; Christopher L Amling; Stephen J Freedland Journal: BJU Int Date: 2018-04-10 Impact factor: 5.588
Authors: Alyssa N Troeschel; Terryl J Hartman; Eric J Jacobs; Victoria L Stevens; Ted Gansler; W Dana Flanders; Lauren E McCullough; Ying Wang Journal: J Clin Oncol Date: 2020-04-06 Impact factor: 44.544
Authors: Ilir Agalliu; Steve Williams; Brandon Adler; Lagu Androga; Michael Siev; Juan Lin; Xiaonan Xue; Gloria Huang; Howard D Strickler; Reza Ghavamian Journal: Cancer Causes Control Date: 2015-03-14 Impact factor: 2.506
Authors: Jill M Hamilton-Reeves; Chelsea N Johnson; Lauren K Hand; Misty D Bechtel; Hilary L Robertson; Carrie Michel; Meredith Metcalf; Prabhakar Chalise; Nicholas J Mahan; Moben Mirza; Eugene K Lee; Debra K Sullivan; Jennifer R Klemp; Christie A Befort; William P Parker; Heather D Gibbs; Wendy Demark-Wahnefried; J Brantley Thrasher Journal: Nutr Cancer Date: 2020-12-09 Impact factor: 2.900
Authors: Mindy C DeRouen; Clayton W Schupp; Jocelyn Koo; Juan Yang; Andrew Hertz; Salma Shariff-Marco; Myles Cockburn; David O Nelson; Sue A Ingles; Esther M John; Scarlett L Gomez Journal: Cancer Epidemiol Date: 2018-01-09 Impact factor: 2.890